Elevation Oncology, Inc. (ELEV)
NASDAQ: ELEV · Real-Time Price · USD
0.3199
+0.0148 (4.85%)
Jun 6, 2025, 4:00 PM - Market closed
Elevation Oncology Stock Forecast
ELEV's stock price has decreased by -91.4% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Elevation Oncology stock ranges from a low of $0.70 to a high of $7.00. The average analyst price target of $2.94 forecasts a 819.04% increase in the stock price over the next year.
Price Target: $2.94 (+819.04%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 24, 2025.
Analyst Ratings
The average analyst rating for Elevation Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 5 | 5 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades $5 | Buy → Hold | Downgrades | $5 | +1,462.99% | Mar 24, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $10 → $0.7 | Buy → Hold | Downgrades | $10 → $0.7 | +118.82% | Mar 21, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy → Hold Downgrades $7 | Buy → Hold | Downgrades | $7 | +2,088.18% | Mar 21, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $9 → $1 | Buy → Hold | Downgrades | $9 → $1 | +212.60% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $1 | Strong Buy | Maintains | $6 → $1 | +212.60% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
n/a
from 33.68M
Revenue Next Year
n/a
EPS This Year
-0.69
from -0.78
EPS Next Year
-0.57
from -0.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.50 | -0.24 | -0.43 | ||
| Avg | -0.69 | -0.57 | -0.69 | ||
| Low | -0.95 | -1.18 | -1.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.